Market Signal Briefing

SharpLink is set to become the first public company to issue its Nasdaq-listed SBET shares natively on Ethereum, appointing Superstate as digital transfer agent to oversee compliant onchain issuance.

Summary

SharpLink plans to tokenize its Nasdaq-listed SBET shares directly on Ethereum.
Superstate’s Opening Bell platform will manage compliant onchain issuance.
The partnership extends beyond issuance, exploring AMM-based trading of tokenized equity.

In an announcement on Sept. 25, SharpLink Gaming, Inc. said it will tokenize its SEC-registered common stock directly on the Ethereum blockchain, appointing financial technology firm Superstate as its Digital Transfer Agent.

The partnership will utilize Superstate’s ‘Opening Bell’ platform for the issuance. The Minneapolis-based company, chaired by Ethereum co-founder Joseph Lubin, stated the move is intended to demonstrate how blockchain infrastructure can create shareholder value and improve market efficiency.

“Tokenizing SharpLink’s equity directly on Ethereum is far more than a technological achievement – it is a statement about where we believe the future of the global capital markets is headed. At SharpLink, our core mission is two-fold: to build the world’s most trusted digital asset treasury and to pursue initiatives that accelerate the global adoption of the Ethereum network.” Lubin said.

Beyond issuance: exploring AMMs and compliant secondary markets
The partnership’s ambitions extend far beyond a simple onchain issuance. SharpLink and Superstate intend to explore one of the most complex frontiers in digital finance: enabling compliant secondary trading of tokenized equity on automated market makers and other DeFi protocols.

This initiative aligns with the SEC’s Project Crypto, a regulatory framework designed to accommodate blockchain-based markets. The goal is to demonstrate how tokenized securities can unlock deeper liquidity and operate within a modernized capital market structure.

If realized, this effort could reposition SharpLink’s tokenized equity and future issuances via Superstate’s Opening Bell as instruments with broader utility than traditional book-entry stock. Trading on AMMs would represent a structural shift in how liquidity forms around public equities, potentially enabling real-time settlement, global investor access, and transparent price discovery in a way conventional exchanges cannot match.

Notably, the partnership with Superstate is a strategic extension of SharpLink’s deep commitment to Ethereum. With Lubin at the helm, the company has aggressively positioned itself as a corporate leader in the Ethereum ecosystem, having launched a significant ETH treasury strategy earlier this year.

Investors have so far met the news with caution. SharpLink’s SBET stock traded down 7.63% on Thursday, settling at $16.26 after opening the session at $16.33 and closing the previous day at $17.58. The drop mirrors a wider pullback across crypto markets but also underscores how experimental the path ahead remains.

Disclaimer

Disclaimer: Blockchain.news provides content for informational purposes only. In no event shall blockchain.news be responsible for any direct, indirect, incidental, or consequential damages arising from the use of, or inability to use, the information provided. This includes, but is not limited to, any loss or damage resulting from decisions made based on the content. Readers should conduct their own research and consult professionals before making financial decisions.

Shiba Inu has continued to raise doubts among traders following consistent rejection of expected breakouts. While its price has remained on the downside, crucial on-chain data provided by CryptoQuant suggests there’s still hope for a breakout soon.

The data shows that a massive 84,734,500,000,000 SHIB are currently held across all crypto exchanges as of September 25, a decent decline from the reserve recorded the previous day.

What does this mean for SHIB?The massive 84.7345 trillion SHIB that is currently held in exchange reserves is flashing a positive sign, despite the 5% decline being witnessed in the price of the asset.

HOT Stories

While exchange reserves basically measure an asset’s liquidity and accessibility, they also play crucial roles in predicting an asset’s potential price action.

According to the data, the total number of SHIB held in all supported crypto exchanges has reduced to 84.7345 trillion, suggesting that traders have become more interested in withdrawing their tokens off exchanges during the period.

Notably, a decline in the value of a crypto asset in reserve indicates lesser selling pressure, which implies growing confidence in the potential price action of the concerned asset. While SHIB has continued to plunge hard, the decreasing reserve shows that traders are increasingly buying off the tokens from the exchanges into cold storage amid surging interest to hold the assets on a long-term basis.

While the declining metric also spans across all derivative exchanges offering SHIB-related options, the decline in the reserve of the derivative exchanges may not directly predict SHIB’s price potential, as traders might be opening both long and short positions. Meanwhile, a rise in reserves across derivatives exchanges would have predicted high price volatility for the token.

Nonetheless, the Shiba Inu momentum has continued to fade, despite the hype surrounding its community engagement. Its recent price action, which saw its price fall as low as $0.00001156, has wiped out gains for short-term traders, while long-term holders appear to be struggling to retain resilience.

With SHIB’s recent on-chain metrics suggesting that bears are taking over its ecosystem, investors are gradually losing optimism, and the possibility of the asset removing another zero is currently threatened.

Nonetheless, a potential breakout in the price of the asset is expected to restore momentum. While a SHIB exec has recently explained that the asset is ready for an ETF review, investors are still confident that SHIB might return to the spotlight soon.

Bitcoin faces critical test as on-chain data reveals market exhaustion Gino Matos · 11 seconds ago · 2 min read

This cycle has absorbed $678 billion in net inflows through realized cap growth, nearly 1.8 times larger than the previous cycle.

2 min read

Updated: Sep. 25, 2025 at 9:05 pm UTC

Cover art/illustration via CryptoSlate. Image includes combined content which may include AI-generated content.

Bitcoin’s (BTC) on-chain data reveals structural concerns about the sustainability of the current rally, and defending the $111,000 zone is fundamental to avoid further downside.

As Glassnode reported on Sept. 25, the retreat from near $117,000 following the Federal Reserve’s rate decision reflects a textbook “buy the rumour, sell the news” pattern.

The current drawdown from Bitcoin’s all-time high of $124,000 to $111,012 represents just a 10.5% decline, modest compared to the cycle’s previous 28% correction or the 60% drops seen in earlier bull markets.

However, the report noted that this surface-level stability masks market exhaustion that warrants careful attention.

On-chain metrics paint a concerning picture of capital flow dynamics. This cycle has absorbed $678 billion in net inflows through realized cap growth, nearly 1.8 times larger than the previous cycle.

Long-term holders have distributed 3.4 million BTC in profits, already exceeding previous cycles and highlighting the magnitude of selling pressure from seasoned investors. The market structure reveals a fragile balance between institutional demand and the distribution of long-term holders.

Bitcoin’s realized profit/loss ratio has reached extreme levels above 10 in 2025, historically indicating cyclical peaks when profit-taking dominates market activity. (Source: Glassnode)US-traded Bitcoin spot ETF inflows, which previously absorbed heavy selling, collapsed from 2,600 BTC per day to nearly zero around the FOMC meeting.

Meanwhile, the long-term holder distribution surged to 122,000 BTC per month, creating an imbalance that set the stage for weakness.

Derivatives markets amplified the correction through forced liquidations and deleveraging. Futures open interest fell sharply from $44.8 billion to $42.7 billion as Bitcoin broke below $113,000, with dense liquidation clusters between $114,000 and $112,000 driving aggressive selling.

While this deleveraging reset cleared excess leverage, it also revealed the market’s vulnerability to liquidity-driven swings.

Options markets reflect heightened downside concerns, with put/call skew spiking from 1.5% to 17% following the correction.

Total options open interest near all-time highs creates a gamma overhang that amplifies volatility, particularly to the downside, where dealers are positioned short gamma.

As Bitcoin is now trading at $109,466, the $111,800 level represented the short-term holder cost basis and served as temporary support during recent selling.

This technical foundation becomes crucial as the market navigates between institutional accumulation and long-term profit-taking by holders.

Bitcoin’s ability to maintain the threshold will determine whether this correction represents healthy consolidation or marks the beginning of a deeper cooling trend.

Without renewed institutional demand to offset continued long-term holder distribution, the risk of more significant price declines increases substantially.

Mentioned in this articleLatest Bitcoin StoriesLatest Alpha Market Report

XRP Ledger’s 2025 boom follows ETF launches and SEC clarity, fueling institutional access and global adoption momentum.The EVM sidechain unlocks Ethereum dApps and DeFi on XRPL, hitting $120M TVL with 1,400 contracts in its debut week.With 19 worldwide events and growing institutional liquidity, XRPL positions itself as a major crypto infrastructure leader.This year, XRP has gone from a position of regulatory uncertainty to one of institutional and technical legitimacy. This combination of factors has led the ecosystem to have one of its busiest years, hosting events worldwide. 

Since Ripple settled its battle with the SEC, XRP’s non-security status has eliminated the primary legal overhang stifling US adoption. Since then, its market performance has increased, and Ripple has found a way to capitalize on the benefits.

From Legal Blockade to Global AdoptionSponsored

This year, the XRP Ledger (XRPL) calendar has been packed. Since January, the ecosystem has hosted 19 events across the globe, ranging from meetups in Greece and summits in Seoul, to bootcamps in Paris and workshops in Germany. 

One thing you know about the XRP community anywhere in the world – they show up in force!

Huge congrats to the @XRPSEOUL team on their first event, and we at @Ripple are absolutely looking forward to the next! https://t.co/g2w0zcHnqv

— Brad Garlinghouse (@bgarlinghouse) September 25, 2025

The enthusiasm with which the community has been organizing these events closely matches the particular level of success the ecosystem has seen this year. 

The resolution of Ripple’s 2020 legal battle with the SEC earlier this year primarily opened the door for significant institutional capital access and accelerated network development. The removal of this regulatory tension immediately paved the way for the launch of institutional products. 

The filing and subsequent launch of spot XRP exchange-traded funds (ETFs) from prominent asset managers like REX-Osprey and Grayscale Investments have introduced significant institutional liquidity and mainstream acceptance.

Sponsored

This development formally classified XRP as a recognized asset class alongside other established cryptocurrencies.

Meanwhile, the blockchain itself has also made significant technological advancements.

A Technological Leap
In the first half of 2025, XRP Ledger successfully launched its Ethereum Virtual Machine (EVM) sidechain.

This technical milestone significantly enhanced the XRPL’s utility, combining the XRPL’s speed, efficiency, and low transaction costs with the versatility and network effect of the broader Ethereum DeFi and dApp community.

Sponsored

The need for smart contracts on XRP is cristal clear. Almost 1.4k smart contracts deployed on Mainnet in only 1 week 🙃 pic.twitter.com/BqSXwNbWLW

— Peersyst Technology (@Peersyst) July 7, 2025

The move generated strong, immediate developer demand, with nearly 1,400 smart contracts deployed in the first week of launch. Shortly after, the ecosystem’s total value locked (TVL) reached an all-time high of $120 million.

The impact of the 2025 breakthroughs contrasts greatly with the preceding years of regulatory uncertainty.

Past Constraints and The Key to Long-Term SuccessSponsored

Many of XRPL’s breakthroughs would not have been possible without the current administration’s open friendliness toward crypto and the SEC’s dropping of the lawsuit against Ripple.

During this legal gridlock, most major US crypto exchanges delisted XRP, barring nearly all regulated institutional participation for over four years. This action isolated the asset from the world’s largest and most compliant financial market.

Throughout this period, protracted litigation created a bottleneck that restrained institutional interest. This context caused XRP’s price to underperform despite the underlying network’s established use cases.

Though XRPL’s reality now paints a different picture, the market is still adapting to the ecosystem’s most recent breakthroughs. Long-term success will heavily depend on sustained utility.

Measuring this success will focus on major institutional projects fully migrating to the chain, sustained developer incentives, and developing real-world applications.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Centrifuge, Janus Henderson, and S&P DJI launched SPXA, the first licensed tokenized S&P 500 index fund.

Summary

Centrifuge, Janus Henderson, and S&P DJI launched the first licensed S&P 500 index fund
The SPXA index will track the S&P 500, making it available for DAOs and on-chain funds

Tokenization is increasingly becoming mainstream on Wall Street. On Thursday, Sept. 25, Centrifuge announced the launch of the Janus Henderson Anemoy S&P 500 Fund (SPXA). The fund is the first S&P 500 index fund licensed by S&P Dow Jones Indices, a leading index provider.

The move represents a significant milestone for real-world assets in crypto. The SPXA fund will provide exposure to the S&P 500 index in on-chain finance, DeFi platforms, and DAOs. Traders will have access to transparent holdings, programmability, and composability across DeFi protocols.

“The benchmarks of traditional finance still shape the global economy, and there’s no index more important than the S&P 500,” said Bhaji Illuminati, CEO of Centrifuge. “Indices are the best way to bring stocks on-chain: they’re simple, collateral-ready, and unlock liquidity in ways individual securities can’t. SPXA is the next step in making every asset investable on-chain, accessible to investors worldwide, around the clock.”

Centrifuge’s SPXA to support liquidity on-chain
Janus Henderson, one of the world’s largest active asset managers with $457 billion in AUM, will serve as sub-investment manager for the fund.

“Launching SPXA with Centrifuge is a natural progression of our blockchain strategy, bringing the world’s most important equity index to a new generation of investors,” said Nick Cherney, Head of Innovation at Janus Henderson. “This is the start of a broader effort to scale our tokenization capabilities and expand secure, efficient access to global markets.”

S&P Dow Jones Indices, the owner and administrator of the S&P 500 index, provides the SPXA tokenized fund with institutional legitimacy.

“Our collaboration with Centrifuge enables investors to gain direct exposure to the S&P 500 Index within a blockchain ecosystem that supports liquidity, transparency, and interoperability,” said Cameron Drinkwater, Chief Product Officer at S&P Dow Jones Indices. “Blockchain is a transformative opportunity for S&P DJI, and Centrifuge is a collaborator with a shared vision to build the future of index-linked financial products.”

TLDR

Spark and PayPal have partnered to integrate PayPal USD into SparkLend for improved liquidity.
Deposits in PayPal USD have surpassed $100 million with plans to scale to $1 billion.
Spark’s risk assessment and liquidity framework help PYUSD gain access to institutional markets.
PayPal USD is now live on the Stellar network, expanding its global reach and use cases.
The partnership positions Spark as a key player in driving stablecoin adoption in the DeFi space.

Spark, an on-chain asset allocator launched by Sky (formerly MakerDAO), has partnered with PayPal to boost liquidity for PayPal USD (PYUSD). This collaboration integrates PYUSD into SparkLend, allowing PayPal’s stablecoin to be utilized in Spark’s decentralized lending markets. As of now, deposits in PYUSD have surpassed $100 million, with expectations to grow to $1 billion.

SparkLend and PayPal USD’s Growth Potential
Since PayPal USD was added to SparkLend, the growth has been significant.

“Predictable access to deep liquidity is crucial for stablecoins like PYUSD to scale,” said Sam MacPherson, co-founder and CEO of Phoenix Labs, a key contributor to Spark.

He emphasized that Spark’s framework proves DeFi can provide stable market foundations necessary for global companies to bring stablecoins into the mainstream.

The Spark platform has a robust model for stablecoin growth. Tokens listed on SparkLend undergo a thorough risk assessment before gaining access to the institutional markets for supply and borrowing. Capital from Spark’s $8 billion-plus stablecoin reserves is deployed via the Spark Liquidity Layer, creating market depth and efficient capital allocation.

Spark’s Liquidity Layer and Stablecoin Adoption
Spark’s liquidity infrastructure positions it as a key player in driving adoption for stablecoins like PYUSD. The platform has already shown its capability to manage large-scale liquidity demands. Spark previously deployed $630 million in on-chain Bitcoin-backed loans to Coinbase, demonstrating its strength in the market.

The stablecoin market is growing rapidly. In just three months, stablecoin supply surged from $235 billion to $263 billion. Daily transaction volumes now regularly exceed $100 billion, showing the increasing demand for stablecoin adoption.

David Weber, Head of PYUSD Ecosystem at PayPal, highlighted the strategic importance of this partnership. “With total DeFi value approaching $150 billion, platforms like Spark are crucial for advancing PYUSD as a cornerstone for DeFi with deep liquidity,” he said. This collaboration helps PYUSD access new markets faster while ensuring compliance and composability from day one.

Expansion of PayPal USD Across Networks
In addition to SparkLend, PayPal USD is also expanding its reach across different blockchain networks. Recently, PYUSD went live on the Stellar network, marking another milestone for PayPal and Stellar. This expansion opens up new wallets, platforms, and business use cases, further extending PYUSD’s global presence.

The launch on Stellar was announced at the Stellar Meridian event in Rio de Janeiro on September 18. This event gathered blockchain leaders, investors, and policymakers, making it a fitting platform for this important announcement. The integration of PYUSD into multiple networks strengthens its position as a leading stablecoin in the DeFi space.

Microsoft has cut off the Israel Ministry of Defense’s access to some of its tech and services after an internal investigation found the organization appeared to be using its tech to store surveillance data on phone calls made by Palestinians.  

The tech giant announced on Thursday that it made the decision to “cease and disable” certain subscriptions from the Israeli military. This affects subscriptions to Azure cloud storage and certain AI services.  

“We do not provide technology to facilitate mass surveillance of civilians, Microsoft Vice Chair and President Brad Smith wrote in a blog post. “We have applied this principle in every country around the world, and we have insisted on it repeatedly for more than two decades. This is why we explained publicly on August 15 that Microsoft’s standard terms of service prohibit the use of our technology for mass surveillance of civilians.”

Microsoft informed Israel of its decision last week, according to The Guardian.  

The decision follows Microsoft’s ongoing review of the matter, which started in August. The investigation was sparked by a story in The Guardian that reported that Unit 8200, the elite Israel military intelligence unit, was using Azure cloud storage to house data on phone calls obtained through the surveillance of Palestinians in Gaza and the West Bank.  

In his blog post, Smith also said the company appreciated The Guardian’s initial reporting. Smith wrote that without it, they wouldn’t have known to look into the matter, as due to customer privacy rights, they can’t access a customer’s content. 

“As employees, we all have a shared interest in privacy protection, given the business value it creates by ensuring our customers can rely on our services with rock solid trust,” Smith wrote.  

Techcrunch event

San Francisco
|
October 27-29, 2025

The company said the review is ongoing but declined to comment to TechCrunch regarding what was still under review.  

Microsoft has been under fire from both employees and outsiders for its involvement with Israel over the past year. Protests regarding Microsoft’s relationship with Israel broke out at the company’s 50th anniversary celebration in April. In August, several employees staged a sit-in at Smith’s office, forcing a lockdown.  

The company has fired multiple employees in recent months for their activism related to Microsoft’s contracts with Israel.   

Becca is a senior writer at TechCrunch that covers venture capital trends and startups. She previously covered the same beat for Forbes and the Venture Capital Journal.

You can contact or verify outreach from Becca by emailing [email protected].

View Bio

Key Takeaways
Goldman Sachs reiterated its "buy" rating on Dick's Sporting Goods as the retailer expands with the acquisition of Foot Locker. Dick's closed its $2.4 billion purchase of its rival earlier this month.Goldman analysts said the combination should further differentiate Dick's from its competitors.

Dick’s Sporting Goods (DKS) stock is getting cheers from Goldman Sachs after the retailer’s $2.4 billion purchase of rival Foot Locker closed earlier this month.

The analysts wrote in a note to clients that a “strong sporting goods industry backdrop along with the global reach and scale of the combined company should result in even stronger vendor relationships which will further differentiate the banners against its competitors.” Dick's moved to acquire Foot Locker in May.

Why This News Matters to Investors
Investors don't always love mergers, which have a reputation of knocking companies off course, producing fewer synergies and savings and more distractions and complexity than expected. Goldman's optimism about the Dick's-Foot Locker deal is a vote of confidence in the deal, which was valued at above $2 billion.

Goldman reiterated a “buy” rating on the stock, adding that with the addition of Foot Locker, it has a price target of $274. That's among the higher targets on Wall Street, according to Visible Alpha, which has a mean near $246. The shares are nearly 2% lower today, falling alongside broader markets, so Goldman's target reflects a roughly 20% premium to recent prices.

“We expect Dick’s management can improve Foot Locker's top line meaningfully as it manages its brand portfolio to include higher brand heat products, improve the store layout, and instill Dick’s service levels, which should help drive conversion," Goldman's analysts wrote.

Nike’s (NKE) change in strategy to refocus on its wholesale partners should give a lift to Foot Locker, which Dick’s plans to operate as a stand-alone business.  

After sinking to a more than one-year low in May, shares of Dick’s Sporting Goods have gradually risen and are roughly unchanged for the year so far.

Do you have a news tip for Investopedia reporters? Please email us at

[email protected]

, /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Fly-E Group, Inc. ("Fly-E" or the "Company") (NASDAQ: FLYE)have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FLY-E (FLYE), CLICK HERE BEFORE NOVEMBER 7, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. 

What Is The Lawsuit About?
The complaint filed alleges that, between July 15, 2025 and August 14, 2025, Defendants failed to disclose to investors that: (1) the Defendants continually praised Fly-E's brand reputation in the industry, cost reductions and favorable pricing from suppliers as a key component for Fly-E's ability to grow its sales network, while simultaneously minimizing risks associated with its lithium battery, supply chain changes and the regulatory environment and possible demand fluctuations for its E-Bikes and E-Scooters; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz,
Email us at: [email protected]
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz,
Telephone: 310-914-5007
Email: [email protected]
Visit our website at: www.frankcruzlaw.com

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

PENSACOLA, Fla.--(BUSINESS WIRE)--A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pensacola, Florida. The hearing will address oral arguments from the plaintiffs and defendants concerning the issue of pre-emption. The pre-emption defence is common in drug litigation. It involves the drug manufacturer arguing that they cannot be sued for failure to warn under state law, because chang.

, /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Tronox Holdings PLC ("Tronox" or the "Company") (NYSE: TROX).

IF YOU SUFFERED A LOSS ON YOUR TRONOX INVESTMENTS, CLICK HERE BEFORE NOVEMBER 3, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?
The complaint filed alleges that, between February 12, 2025 and July 30, 2025, Defendants failed to disclose to investors that: (1) the Company was ill-equipped to adequately forecast demand for its pigment and zircon products or otherwise minimize the impact of potential demand fluctuations; (2) the Company continued to promote its lofty margin projections which relied upon continually increased sales volumes in its pigment and zircon division; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224) 
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us: 
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067

Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay & Murray LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Amazon has reached a historic $2.5bn (£1.9bn) settlement with a US business watchdog over allegations it tricked customers into signing up for Prime membership.

The Federal Trade Commission (FTC) accused the online giant of tricking customers into the membership scheme - which includes perks like faster delivery - and then making it difficult to cancel.

The Seattle-based company will pay $1bn (£750m) in civil penalties, and $1.5bn (£1.1bn) paid back to customers unintentionally enrolled in Prime or deterred from cancelling their subscriptions.

Around 35 million Prime customers will be eligible for a payout from the $1.5bn (£1.1bn) fund, the FTC said.

Customers who signed up for Prime between 23 June, 2019, and 23 June, 2025, through certain offers, and used few Prime benefits afterwards, will automatically receive $51 (£38).

The FTC accused Amazon of making it deliberately difficult for customers to purchase an item without also subscribing to Prime.

It added that customers were, in some cases, presented with a button to complete their transactions, which did not clearly state that it would enrol them into Prime.

Image:
Amazon did not admit any wrongdoing. Pic: Reuters

Getting out of a subscription was often too complicated, and Amazon slowed or rejected changes that would have made cancelling easier, according to an FTC complaint.

The process of unsubscribing, requiring customers to affirm on three pages their desire to quit, was referred to internally as "Iliad", an ancient Greek epic by Homer about the Trojan War, according to the watchdog's complaint.

The settlement came just days after a trial began in Seattle this week.

Chris Mufarrige, director of the Bureau of Consumer Protection, said: "I think it just took a few days for them to see that they were going to lose. And they came to us and they paid out."

Amazon, which admitted no wrongdoing in the case filed two years ago, said it was confident it would win the case but chose to resolve it quickly rather than going through potentially years of trial and appeal.

Image:
Prime benefits include faster delivery. Pic: Reuters

Amazon spokesman, Mark Blafkin, said: "Amazon and our executives have always followed the law and this settlement allows us to move forward and focus on innovating for customers.

"We work incredibly hard to make it clear and simple for customers to both sign up or cancel their Prime membership, and to offer substantial value for our many millions of loyal Prime members around the world."

Under the settlement, Amazon is prohibited from misrepresenting the terms of the subscriptions.

It must fully disclose the costs to be incurred and obtain the customer's express consent for the charge, with a clear option for customers to accept or decline a Prime subscription offered during purchase and avoid language deemed confusing, such as: "No thanks, I don't want free shipping."

Amazon said the settlement does not require it to make any additional changes, only to maintain its current sign-up and cancellation process that it had put in place for a year.

Chipmaker Intel has approached Taiwan Semiconductor Manufacturing Company about investments in manufacturing or partnerships, the Wall Street Journal reported on Thursday, citing people familiar with the matter.

Shares of Coca-Cola Co (NYSE:KO) were last seen down 0.6% to trade at $66.06, after the company was issued a price-target cut from Wells Fargo to $75 from $78. While the beverage name has been struggling of late, the stock is still up 6.1% in 2025, and looks to be within one standard deviation of a historically bullish trendline.

The equity is holding near its 24-month moving average, a trendline it has closed above in 80% of the last 20 months. According to Schaeffer’s Senior Quantitative Analyst Rocky White, this has happened 14 times over the last 20 years, after which the equity was higher one month later 71% of the time, averaging a 4.2% jump. A move of similar magnitude from the stock's current perch would put it above $68.

Options traders are pricing in relatively low volatility expectations, per the shares' Schaeffer's Volatility Index (SVI) of 17%, which ranks in the 14th percentile of readings from the past 12 months.

PALO ALTO, Calif., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has entered into an agreement to make a $150 million Bitcoin (BTC) investment in Datavault AI Inc. (Nasdaq: DVLT, “Datavault”), which is intended to provide growth capital to Datavault to accelerate its supercomputing infrastructure, expand independent data exchanges, and unlock new revenue streams.  

Datavault AI’s patented platform is positioned to capture value across biotech, energy, and entertainment markets, as the global AI market is projected to reach $1.8 trillion by 2030 and the life sciences analytics market was estimated at $35.69 billion in 2024, forecasted to grow at an 11.4% CAGR through 2030. By leveraging Web 3.0, blockchain-secured data trading, and AI-driven analytics, the company delivers secure, scalable solutions addressing trust, data integrity, and monetization challenges.

The strategic investment is intended to capture growth in the biotech data monetization market, which is expected to reach a market size of $30-50 billion by 2024. Scilex intends to leverage its expertise in the biotech and pharmaceutical space to create a potential marketplace for the Real-World Assets (RWA) in the biotech and pharmaceutical industry that are tokenized on a blockchain to represent their ownership in digital form.

Under the terms of the purchase agreement between Datavault and Scilex, Scilex is expected to receive up to an aggregate of 278,914,094 shares of Datavault common stock (at an effective purchase price of $0.5378 per share) ( subject to adjustment for stock splits and similar transactions), with 15,000,000 shares to be issued at the closing of the initial tranche of Scilex’s investment and the remainder to be issued in the second tranche in the form of a pre-funded warrant without beneficial ownership limitations to be issued to Scilex following the approval by Datavault’s stockholders of, among other things, the issuance of Datavault shares to Scilex in excess of 19.99% of Datavault’s total pre-financing shares outstanding. Datavault’s board and management remain unchanged, though Scilex will have the right to nominate two directors to the Company’s board for so long as Scilex maintains beneficial ownership of at least 10% of the Company’s common stock, and the right to nominate one director for so long as Scilex maintains beneficial ownership of at least 5% but no more than 10% of the Company’s common stock.  

Henry Ji, Ph.D., CEO, President and Chairman of the Board of Scilex Holding Company, said, "Datavault's cutting-edge technologies align perfectly with the biotech sector's need for advanced data analytics, AI-driven insights, and super computing power. This investment reflects our belief in Datavault’s ability to transform markets where trust and precision are critical. Biotech is a market we know well, and we will help guide Datavault to maximum revenue generation in our sector while Datavault expands across the global economy. With our resources and their patented technology, we see an incredible opportunity to drive real global impact together.”

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

[email protected]

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

About Semnur Pharmaceuticals, Inc.

Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.

Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California, and is a majority owned subsidiary of Scilex.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring.

The company is headquartered in Beaverton, OR.

Learn more about Datavault AI at www.dvlt.ai

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Scilex’s proposed investment in Datavault, timing thereof and anticipated use of bitcoin proceeds as growth capital for Datavault’s expansion plans, the market size of the biotech data monetization market, Scilex’s plans to create a potential marketplace for RWA in the biotech and pharmaceutical industry, Scilex’s plans to appoint directors to the Datavault board, potential Datavault stockholder approval,   future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to achieve the benefits of the transactions contemplated with Datavault, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Datavault; the risk that the transactions contemplated with Datavault disrupts current plans and operations; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: [email protected]

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

What a past month it's been for shares of nuclear innovation play Oklo (NASDAQ:OKLO), which are still up close to 88%, even after Wednesday's painful 8% pullback.

, /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against LifeMD, Inc. ("LifeMD" or the "Company") (NASDAQ: LFMD).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LIFEMD, INC. (LFMD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE OCTOBER 27, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between May 7, 2025 and August 5, 2025, Defendants failed to disclose to investors that: (1) Defendants materially overstated LifeMD's competitive position; (2) Defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3 )as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

SOURCE Law Offices of Howard G. Smith

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Key Takeaways Colgate combines pricing actions and productivity moves to expand margins and efficiency.CL leverages AI, analytics and premiumization to optimize portfolio and marketing.Oral Care relaunches and skincare trade-ups drive share gains and brand momentum.
Colgate-Palmolive Company (CL - Free Report) is effectively leveraging its pricing power to support growth and mitigate external cost pressures. The company’s productivity program centers on cost savings and efficiency initiatives designed to strengthen its operational foundation. CL’s pricing strategy includes competitive pricing, value-based tactics and price segmentation to address diverse consumer needs while optimizing value.

Colgate sets prices comparable to its competitors, emphasizing the value and benefits of its products, thereby offering a range of prices to suit different consumer budgets. The company is benefiting from key pricing actions, coupled with its funding-the-growth program and other productivity moves, aimed at driving efficiency and expanding margins.

The company is focused on optimizing the global supply chain for greater agility and resilience, leveraging AI and data analytics to refine portfolio and promotional decisions, and prioritizing investments in high-return areas. By balancing core innovation with premiumization, Colgate is positioning itself to capture growth opportunities and reinforce its leadership in daily-use consumer categories.

Colgate continues to prioritize innovation as a key driver of growth across categories, geographies and price tiers. Management highlighted that premium innovation is fueling momentum, with recent launches such as Colgate Miracle Repair serum, EltaMD UV Skin Recovery, and relaunches of Colgate Total, Sanex, Protex, Suavitel, and Hill’s therapeutic lines. Such initiatives are helping strengthen brand health and expand household penetration by bringing consumer-perceived value at every price point.

In Oral Care, the global relaunch of Colgate Total with a full regimen of toothpaste, toothbrush and mouthwash is delivering incremental share gains, particularly in Latin America and Asia. Beyond Oral Care, Colgate’s skincare brands, including EltaMD and PCA Skin, remain growth engines, supported by consumer trade-ups to premium offerings. The company is also accelerating investment in digital, data, analytics and AI to sharpen its innovation model and optimize marketing execution. Such efforts are likely to continue driving sustained growth and profitability.

CL’s Price Performance, Valuation and EstimatesColgate’s shares have lost 12.5% year to date compared with the industry’s 8.1% dip.

Image Source: Zacks Investment Research

From a valuation standpoint, CL trades at a forward price-to-earnings ratio of 20.99X compared with the industry’s average of 19.09X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for CL’s 2025 and 2026 EPS indicates year-over-year growth of 2.2% and 6.9%, respectively. The company’s EPS estimate for 2025 and 2026 has been stable in the past 30 days.

Image Source: Zacks Investment Research

Colgate currently carries a Zacks Rank #3 (Hold). 

Stocks to Consider in the Consumer Staples Space The Chefs' Warehouse, Inc. (CHEF - Free Report) distributes specialty food and center-of-the-plate products in the United States, the Middle East and Canada. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. 

The Zacks Consensus Estimate for The Chefs' Warehouse’s current financial-year sales and earnings indicates growth of 6.6% and 19.1%, respectively, from the prior-year levels. CHEF delivered a trailing four-quarter earnings surprise of 11.3%, on average.

Celsius Holdings, Inc. (CELH - Free Report) , which is specialized in nutritional functional foods, beverages and dietary supplements, starches and nutrition ingredients, currently sports a Zacks Rank of 1.

The Zacks Consensus Estimate for Celsius’ current financial-year earnings is expected to rise 54.3% from the corresponding year-ago reported figure. CELH delivered a trailing four-quarter earnings surprise of 5.4%, on average.

Post Holdings (POST - Free Report) , which is a consumer-packaged goods holding company, currently carries a Zacks Rank #2 (Buy). POST delivered a trailing four-quarter earnings surprise of 21.4%, on average. 

The Zacks Consensus Estimate for Post Holdings’ current financial-year earnings indicates growth of 11% from the year-ago number. 

CNBC's Julie Sweet joins 'Squawk on the Street' to discuss insights on Accentures latest quarter, how clients are utilizing AI, and much more.

The Company's first location in the state is now accepting patients.

, /PRNewswire/ -- Today, Encompass Health, the nation's largest owner and operator of inpatient rehabilitation hospitals, announced the opening of its first location in the state of Connecticut: Encompass Health Rehabilitation Hospital of Danbury.

Encompass Health Rehabilitation Hospital of Danbury

The 40-bed, 50,500-square-foot freestanding hospital provides essential rehabilitation services that help patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions regain functional ability, independence and quality of life. Patients receive a minimum of three hours of intensive physical, occupational and/or speech therapy five days each week, as well as frequent physician visits and 24-hour nursing care. An interdisciplinary team of highly specialized nurses, therapists and physicians create customized treatment plans to meet each patient's unique recovery goals.

"We're thrilled to bring Encompass Health's high-quality inpatient rehabilitation services to the state of Connecticut," said Mat Gooch, president of Encompass Health's Northeast region. "This hospital will fulfill an important need in the community, enabling patients in the greater Danbury area to recover from serious illnesses and injuries close to their loved ones."

Designed with patients' needs in mind, the hospital will offer amenities such as 40 private patient rooms; a spacious, light-filled therapy gym featuring advanced rehabilitation technologies for every mobility level; an activities of daily living suite with real-world simulated spaces; an in-house dialysis suite; a landscaped therapy courtyard with recreational areas; a dining room; an in-house pharmacy and dayroom areas.

Encompass Health Danbury is Encompass Health's 170th hospital nationwide and its first location in the state of Connecticut.

To learn more, visit encompasshealth.com/locations/danbury-rehab.

About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 170 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.

From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.

Encompass Health media contact:
Polly Manuel | 205-970-5912
[email protected]

SOURCE Encompass Health Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Key Takeaways Schwab is considering giving retail investors direct access to private companies.CEO Rick Wurster said growing private firms make expanded access a priority.Robinhood has also filed plans for a fund, giving everyday investors private access.
Charles Schwab (SCHW - Free Report) has been wanting to allow retail investors direct access to private companies. In an interview with Bloomberg Television, as published in an MSN article, SCHW’s CEO and president, Rick Wurster, said that the brokerage giant is exploring ways to permit everyday investors to buy into private companies like fintech giant Stripe and artificial-intelligence firm OpenAI.

Wurster stated, “There’s a lot more private companies today than there used to be, and fewer public companies. It makes sense to think about providing direct access to retail investors to private companies, and that’s something we’re looking at.”

He added, “We would love to see retail investors be able to participate in the growth of private companies in our country.”

Schwab’s latest comments regarding providing broader access to private firms come after the firm announced in April that it will make its new alternative investments platform, Schwab Alternative Investments Select, completely available to all its eligible retail clients who hold household assets worth more than $5 million.

Such efforts have been encouraged of late, as there has been an increasing demand among wealthy clients to tap into private market opportunities in order to meet their portfolio diversification needs.

Schwab’s Competitor Taking Similar StepsEarlier this month, Robinhood Markets (HOOD - Free Report) filed plans with the Securities and Exchange Commission to launch a venture capital fund, Robinhood Ventures Fund I (“RVI”), aimed to provide everyday investors access to private companies before they go public. If approved, the RVI will invest in a small basket of private companies across industries and hold them through IPO and beyond.

Robinhood’s chairman and CEO, Vlad Tenev, said, “For decades, wealthy people and institutions have invested in private companies while retail investors have been unfairly locked out.”

Schwab’s Price Performance & Zacks RankSo far this year, SCHW shares have gained 24.8% compared with the industry’s growth of 30%.

Image Source: Zacks Investment Research

Currently, Schwab carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

A better-ranked brokerage company is Interactive Brokers Group (IBKR - Free Report) . Currently, IBKR carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for Interactive Brokers’ 2025 earnings has been revised 1.6% upward over the past 60 days. IBKR shares have gained 45.9% so far this year.

Jabil Inc. (NYSE:JBL) Q4 2025 Earnings Call September 25, 2025 8:30 AM EDT

Company Participants

Adam Berry - Senior Vice President of Investor Relations & Communications
Gregory Hebard - Chief Financial Officer
Steven Borges - Executive Vice President of Global Business Units
Matt Crowley - Executive Vice President of Global Business Units
Andy Priestley - Executive Vice President of Global Business Units
Michael Meheryar Dastoor - CEO & Director
Frederic McCoy - Executive Vice President of Operations
Francis McKay - Senior VP and Chief Supply Chain & Procurement Officer
Mark Mondello - Executive Chairman

Conference Call Participants

Ruplu Bhattacharya - BofA Securities, Research Division
Mark Delaney - Goldman Sachs Group, Inc., Research Division
Steven Fox - Fox Advisors LLC
Melissa Dailey Fairbanks - Raymond James & Associates, Inc., Research Division

Presentation

Operator

Greetings, and welcome to the Jabil Fourth Quarter and Fiscal Year 2025 Financial Results and Investor Briefing. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Adam Berry. Please go ahead, sir.

Adam Berry
Senior Vice President of Investor Relations & Communications

Good morning, and welcome to Jabil's Fourth Quarter and Fiscal Year 2025 Earnings Call. This is also Jabil's eighth Annual Investor Briefing. I'm Adam Berry, Senior Vice President of Investor Relations and Corporate Affairs. This is an important day for us at Jabil, and we appreciate your continued interest in our company.

Our investor briefing is always one of the highlights of our calendar. It's our opportunity to step back from the quarter-to-quarter rhythm and give you a deeper look at how we're shaping the business, how we're allocating capital, and how we're positioning Jabil for sustainable long-term growth.

Before we dive in, I need to cover a quick but important point. Some of the information you'll hear during our discussion today will consist of forward-looking statements, including, without limitation, those

Recommended For You

The Investment Committee give you their top stocks to watch for the second half.

CNBC's MacKenzie Sigalos joins 'Money Movers' with the latest news.